Human GPA Protein
Catalog No: GPA-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human GPA Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Ser20-Glu91 (accession: AAA52768.1).
Product Details
- Molecular Aliases
- Glycophorin-A; Glycophorin A; PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN;PAS2
- Protein Length
- Ser20-Glu91
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 34.7 kDa. Due to glycosylation, the protein migrates to 45-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human GPA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human GPA is greater than 95% as determined by SEC-HPLC.
Human GPA, hFc Tag immobilized on CM5 Chip can bind Anti-GPA Antibody, hFc Tag with an affinity constant of 0.17 μM as determined in SPR assay (Biacore S200). (QC Test)
Background
Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine. The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.
References
- Grygiel-Górniak B, Limphaibool N, Perkowska K, Puszczewicz M. Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018 Sep;130(7):581-596. doi: 10.1080/00325481.2018.1503920. Epub 2018 Aug
- PMID:
- Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.